Ergoteles’s Cymabay Therapeutics CBAY Stock Holding History

Ergoteles’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-103,997	Closed	-$652K	–	1897
2022 Q4	$652K	Sell	103,997 -180,163	-63%	-$685K	0.02%	607
2022 Q3	$995K	Sell	284,160 -126,240	-31%	-$453K	0.04%	486
2022 Q2	$1.21M	Buy	+410,400	New	+$980K	0.04%	464
2021 Q1	–	Sell	-98,400	Closed	-$565K	–	1129
2020 Q4	$565K	Buy	+98,400	New	+$745K	0.02%	431

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ergoteles's CBAY Position: Q1 2023 in Review

Ergoteles sold out of Cymabay Therapeutics (CBAY) in Q1 2023, closing a stake of 103,997 shares — an estimated $652K sold.

Ergoteles first reported a position in CBAY in Q4 2020 and held it in 4 quarters. The position peaked at $1.21M in Q2 2022. 139 funds tracked by Wall St. Rank hold CBAY as of Q1 2023.

Ergoteles reported no remaining Cymabay Therapeutics position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 103,997 Cymabay Therapeutics shares in Q1 2023, an estimated $652K.
Ergoteles first reported a position in Cymabay Therapeutics in Q4 2020 and held it in 4 quarters.
Ergoteles's Cymabay Therapeutics position peaked at $1.21M in Q2 2022.
139 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.